|
|
|
|
Zevalin Data to be Presented at ASH 2008
12 presentations and posters on ZEVALIN(R) in Non-Hodgkin's Lymphoma scheduled SEATTLE, December 04, 2008 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc.(CTI) today announced presentations or posters of interest related to Zevalin...
|
|
|
Zevalin Data to be Presented at ASH 2008
SEATTLE, Dec.4 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) today announced presentations or posters of interest related to Zevalin (ibritumomab tiuxetan) to be presented at the 50th Annual Meeting of...
|
|
|
Zevalin Data to be Presented at ASH 2008
12 presentations and posters on ZEVALIN(R) in Non-Hodgkin's Lymphoma scheduled SEATTLE, Dec.4 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) today announced presentations or posters of interest related to Zevalin(R) ...
|
|
|
Zevalin Data to be Presented at ASH 2008
-7:30 PM 1144 Poster I-249 Radioimmunotherapy (90Y- Zevalin(R)) Combined with BEAM Conditioning Regimen and Autologous Stem Cell Transplantation for the Treatment of Non Hodgkin Lymphomas: Results of An Italian Multicenter Study Sunday...
|
|
|
S&P: Biogen Idec Inc. Rating Raised to 'BBB+', Off CreditWatch; Outlook Is Stable
--Standard & Poor's Ratings Services said today that it raised its ratings, including the corporate credit rating, on biopharmaceutical company Biogen Idec Inc.to 'BBB+' from 'BBB'. The outlook is stable. The ratings have been...
|
|
|
Cancer Prevention Coalition Comments on The Obama Cancer Plan
CHICAGO--(BUSINESS WIRE)--Dec.02, 2008--Obama is the first President-elect to develop a comprehensive cancer plan, besides doubling cancer funding. The plan defines and coordinates the responsibilities of four federal agencies: the...
|
|
|
Use of oral glucocorticoids and risk of skin cancer and non-Hodgkin's lymphoma: A population-based case&#8
Study to investigate whether use of oral glucocorticoids was associated with an increased risk of developing basal cell carcinoma (BCC), squamous cell carcinoma (SCC), malignant melanoma (MM), and non-Hodgkin's lymphoma (NHL) 5422 BCC,...
|
|
|
Cell Therapeutics's Zevalin sBLA wins FDA priority review
Cell Therapeutics, a biopharmaceutical company, has announced that the FDA has accepted for filing and review, and has granted priority review status for, the supplemental biologics license application for use of Zevalin as consolidation...
|
|
|
Spectrum Pharmaceuticals Announces Zevalin sBLA Granted Priority Review by the FDA; Target Decision (PDUFA) Da
Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need.This does not represent any evaluation of the adequacy of the data submitted. A Prescription Drug User Fee Act (PDUFA) target date of...
|
|
|
Variations in gene activity can predict the survival of patients with lymphoma
Patterns of gene activity in a type of non-Hodgkin lymphoma has given researchers a better understanding of factors that contribute to the survival of patients treated for the disease.Gene activity, or expression, is a measure of...
|
|
|
Micromet to Present at the Piper Jaffray 20th Annual Health Care Conference
BETHESDA, Md., Nov.26 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced that its President...
|
|
|
Allos Therapeutics to Host Analyst and Investor Briefing on Monday, December 8, 2008
- Allos Therapeutics, Inc.(NASDAQ:ALTH), a biopharmaceutical company focused on developing and commercializing innovative small molecule drugs for the treatment of cancer, today announced that it will host an analyst and investor briefing...
|
|
|
Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2
SOUTH SAN FRANCISCO, Calif., Dec.3 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular disease, inflammatory disease and cancer, today...
|
|
|
Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
SOUTH SAN FRANCISCO, Calif., Dec.3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced that members of Rigel's senior management team will host a conference call with simultaneous webcast on Sunday, December 7, 2008,...
|
|
|
Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2
SOUTH SAN FRANCISCO, Calif., Dec.3 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular disease, inflammatory disease and cancer, today...
|
|
|
Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
today announced that members of Rigel's senior management team will host a conference call with simultaneous webcast on Sunday, December 7, 2008, at 4:00 p.m.PST, to discuss the results of Rigel's Phase 2 clinical trial of R788, an oral...
|
|
|
Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society
/PRNewswire-FirstCall/ -- Micromet, Inc., a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, will host a webcast and conference call on, Monday, December...
|
|
|
Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2
SOUTH SAN FRANCISCO, Calif., Dec.3 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular disease, inflammatory disease and cancer, today...
|
|
|
Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
SOUTH SAN FRANCISCO, Calif., Dec.3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced that members of Rigel's senior management team will host a conference call with simultaneous webcast on Sunday, December 7, 2008,...
|
|
|
Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society
BETHESDA, Md., Dec.3 /PRNewswire-FirstCall/ -- Micromet, Inc. , a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, will host a webcast and conference...
|
|
|
Weta Ray Clark Succumbs to Cancer
N&O editor Clark never wavered as readers' friend Weta Ray Clark's humble spirit helped push herself, others for better ideas.Staff File Photo Story Tools More Local & State Most Popular Stories E-mailed Last 7 Days Last...
|
|
|
Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2
SOUTH SAN FRANCISCO, Calif., Dec.3 /PRNewswire/ -- Portola Pharmaceuticals, a biopharmaceutical company developing innovative drugs that provide significant advances in cardiovascular disease, inflammatory disease and cancer, today...
|
|
|
Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH
SOUTH SAN FRANCISCO, Calif., Dec.3 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. today announced that members of Rigel's senior management team will host a conference call with simultaneous webcast on Sunday, December 7, 2008,...
|
|
|
Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Presented at American Society
BETHESDA, Md., Dec.3 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI - News), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, will host a...
|
|
|
Zevalin Granted Priority Review for Additional Indication
The FDA has granted priority review status for Cell Therapeutics SBLA for Zevalin (ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin lymphoma who achieve a response to first-line therapy.
|
